Overview
Resistance to antineoplastic drug is a disorder.
Auto-generated from clinical reference data. Not a substitute for medical advice.
Treatments & Interventions
Research Evidence
Peer-reviewed studies linked via MeSH term "Drug Resistance, Neoplasm" from the MEDLINE/PubMed database.
Sort:
Epigenetic mechanisms of PARP inhibitor resistance in ovarian cancer: A systematic review with bioinformatic analysis of clinically actionable genes.
[object Object], [object Object] · Crit Rev Oncol Hematol · 2026
PMID: 41223982Meta-Analysis
SLC7A11 as a molecular nexus of prognosis, resistance, and therapeutic roadmap in cancer: A systematic review and meta-analysis.
[object Object], [object Object], [object Object] et al. · Int J Biol Macromol · 2026
PMID: 41308763Meta-Analysis
Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti-CD38 Monoclonal Antibodies: A Systematic Review.
[object Object], [object Object], [object Object] et al. · Cancer Med · 2025
KEAP1 mutations as key crucial prognostic biomarkers for resistance to KRAS-G12C inhibitors.
[object Object], [object Object], [object Object] et al. · J Transl Med · 2025
Human equilibrative nucleoside transporter 1 and concentrative nucleoside transporter 1 in colorectal cancer: What do we know? A systematic review.
[object Object], [object Object], [object Object] et al. · Histol Histopathol · 2025
PMID: 39916554Meta-Analysis
Real world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: a meta-analysis of clinical studies.
[object Object], [object Object], [object Object] et al. · BMC Pharmacol Toxicol · 2025
p27and cytoplasmic pSer10p27 are promising biomarkers for predicting prognosis and chemotherapy response in ovarian cancer.
[object Object], [object Object], [object Object] et al. · Histol Histopathol · 2025
PMID: 38818655Meta-Analysis
Meta-analysis of the efficacy and adverse effects of acalabrutinib in the management of relapsed/refractory chronic lymphocytic leukemia.
[object Object], [object Object], [object Object] et al. · J Chemother · 2025
PMID: 38803142Meta-Analysis
Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis.
[object Object], [object Object], [object Object] et al. · Leuk Lymphoma · 2025
PMID: 39756041Meta-Analysis
Systematic Review and Meta-analysis Indicating Curcumin to Enhance the Synergistic Potential of Paclitaxel and Reduce Cell Viability, Tumor Volume, and Drug Resistance in Different Cancers.
[object Object], [object Object], [object Object] et al. · Curr Med Chem · 2025
PMID: 39238389Meta-Analysis
Search all PubMed articles for Resistance to antineoplastic drug
Research data from MEDLINE/PubMed
Related Conditions
Quick Facts
- SNOMED CT
- 720580006
- UMLS CUI
- C0282588
- Fully Specified Name
- Resistance to antineoplastic drug (disorder)
- Specialists
- 0
- Diagnostic Biomarkers
- 0
- Known Treatments
- 2
Medical Disclaimer
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.
Clinical content is derived from the SNOMED CT clinical ontology and curated medical knowledge graphs.